Drug Trial Radar · NCT05607680
A Study of IBI362 in Participants With Obesity or Overweight
Last checked: Nov 19, 2026Latest source record: Nov 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
610
Actual
Start
Nov 14, 2022
Primary completion
Aug 21, 2023
Study completion Apr 16, 2024
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of IBI362 in overweight or obese subjects. Subjects will be randomly assigned to IBI362 low-dose, high-dose and placebo groups. The entire trial cycle includes a 2-week screening period, a 48-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.
Conditions
- Obesity Or Overweight
Interventions
PlaceboDrug
Placebo administered subcutaneously (SC) once a week.
IBI362Drug
IBI362 administered subcutaneously (SC) once a week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change from Baseline in Body WeightTime frame: Baseline, Week 32
- Percentage of Participants who Achieve ≥5% Body Weight ReductionTime frame: Week 32
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Xuancheng People's Hospital
Xuancheng, Anhui, China
People's Hospital of Peking University
Beijing, Beijing Municipality, China
Luoyang Third People's Hospital
Luoyang, He'nan, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, He'nan, China
The First Affiliated Hospital of Nanyang Medical University
Nanyang, He'nan, China
The Third Affiliated Hospital of Xinxiang Medical University
Xinxiang, He'nan, China
Hebei Petro China Central Hospital
Langfang, Hebei, China
The First People's Hospital Of Kunshan
Kunshan, Jiangsu, China
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Affiliated Hospital Of Nantong University
Nantong, Jiangsu, China
Suzhou Municipal Hospital
Suzhou, Jiangsu, China
Pingxiang People's Hospital
Pingxiang, Jiangxi, China
China-Japan Union Hospital of Jilin University
Changchun, Jilin, China
Shenyang Fifth People's Hospital
Shenyang, Liaoning, China
Jinan Central Hospital
Ji'nan, Shandong, China
Shandong Provincial Third Hospital
Ji'nan, Shandong, China
Qilu Hospital Of Shandong University (Qingdao)
Qingdao, Shandong, China
Tai'an Central Hospital
Tai’an, Shandong, China
Zibo Municipal Hospital
Zibo, Shandong, China
Shanxi Bethune Hospital
Taiyuan, Shanxi, China
Yan'an University Xianyang Hospital
Xianyang, Shanxi, China
Huzhou Central Hospital
Huzhou, Zhejiang, China
Lishui Central Hospital
Lishui, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.